Skip to main content

Table 1 Summary of patients with endophthalmitis following intravitreal injection of anti-VEGF agent

From: Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms

Patient

Diagnosis

Medication

Pre-injection VA

VA at presentation

Days to presentation

Treatment

Culture results

Continued anti-VEGF?

Final VA

Length of follow-up (months)

1

BRVO/CME

Bevacizumab

20/50

CF

2

Tap/inject

CONS

N

20/40 − 1

12

2

BRVO/CME

Bevacizumab

20/100

HM

3

Tap/inject, then PPV

CONS

Y

20/125

23

3

CRVO/CME

Bevacizumab

20/40

CF

15

PPV

CONS

N

HM

26

4

DME

Bevacizumab

20/60

CF

4

Tap/inject

CONS

Y

20/80

22

5

NVAMD

Bevacizumab

20/40 − 2

20/80

3

Tap/inject

CONS

Y

20/80

25

6

Radiation retinopathy s/p plaque therapy for MM

Ranibizumab

20/200

HM

3

Tap/inject

CONS

Y

20/250

11

7

NVAMD

Ranibizumab

20/100

CF

7

Tap/inject, then PPV

CONS

N

20/160, ph 20/125

13

8

DME

Bevacizumab

? (elsewhere)

HM

4

Tap/inject, then PPV

CONS

Y

20/40

10

9

CRVO/CME

Ranibizumab

20/63

CF

3

Tap/inject

Corynebacterium

Y

20/80

23

10

MC/CNV

Ranibizumab

20/25

HM

1

Tap/inject, then PPV

Strep viridans, Neisseria

Y

20/160

16

11

NVAMD

Bevacizumab

? (elsewhere)

20/400

4

Tap/inject, then PPV

E. coli, Enterobacter cloacae

N

20/50 + 2

4

12

NVAMD

Bevacizumab

20/126

20/100

4

Tap/inject, then PPV

Lactococcus garvieae, CONS

Y

20/40

18

13

NVAMD

Bevacizumab

20/80

CF

5

Tap/inject

No growth

Y

20/150

22

14

CRVO/CME

Bevacizumab

20/250 − 3

HM

4

Tap/inject

No growth

N

HM

4

15

NVAMD

Ranibizumab

20/200 − 2

1/200

4

Tap/inject

No growth

N

CF

21

16

CRVO/CME

Ranibizumab

?

20/100

3

Tap/inject

No growth

Y

?

1

  1. Summary of patients with endophthalmitis following intravitreal injection of anti-VEGF agent
  2. Abbreviations: VA visual acuity, BRVO branch retinal vein occlusion, CRVO central retinal vein occlusion, CME cystoid macular edema, DME diabetic macular edema, NVAMD neovascular age-related macular degeneration, MC multifocal choroiditis, CNV choroidal neovascularization, MM malignant choroidal melanoma, CF counting fingers, HM hand motions, PPV pars plana vitrectomy, CONS coagulase-negative Staphylococcus